Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Pharm Pat Anal. 2023 Mar;12(2):79-85. doi: 10.4155/ppa-2023-0001. Epub 2023 May 4.
Current medications for Alzheimer's disease help manage symptoms and behavioral problems. Nevertheless, they do not slow the progression of cognitive decline or dementia. A potential approach for treating Alzheimer's disease is to target neurons that are sensitive to disease pathobiology such as glutamatergic neurons. Several patents disclosed methods for treating Alzheimer's disease by administering riluzole or its prodrugs. Clinical trials revealed that 6 months treatment using riluzole or troriluzole is associated with a slower decline in the tomographic measures of the positron emissions of cerebral glucose metabolism in Alzheimer's patients. The proposed strategy claims to prevent and/or slow the cognitive decline of Alzheimer's patients and to enhance global functioning. These claims may also pave the way for other glutamate modulators to be used for Alzheimer's disease.
目前用于治疗阿尔茨海默病的药物有助于控制症状和行为问题。然而，它们并不能减缓认知能力下降或痴呆的进展。治疗阿尔茨海默病的一种潜在方法是针对对疾病病理生物学敏感的神经元，如谷氨酸能神经元。几项专利公开了通过给予利鲁唑或其前药来治疗阿尔茨海默病的方法。临床试验显示，使用利鲁唑或托利鲁唑治疗 6 个月与阿尔茨海默病患者脑葡萄糖代谢正电子发射断层扫描测量的下降速度较慢有关。该提议的策略旨在预防和/或减缓阿尔茨海默病患者的认知能力下降，并增强整体功能。这些说法也可能为其他用于治疗阿尔茨海默病的谷氨酸调节剂铺平道路。
